In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy.
The development of generic versions of innovator medicines is a global public health need.
Dr. Wesley (Wes) Workman, USP Volunteer and Chair, General Chapters–Biological Analysis Expert Committee reflects on his volunteer role at USP and his work with what he refers to as the "dream team" of the heparin world.
As more drug makers adopt pharmaceutical continuous manufacturing, new technological developments and operational demands are resulting from new partnerships among academic centers and industry leaders, particularly in the past two years. To this goal, USP recently formalized collaborations with Center for Structured Organic Particulate Systems (C-SOPS), a leader in research on PCM. Learn more about the opportunities in this field.
International Pharmaceutical Federation CEO Luc Besançon guest blogs about how to combat fake medicines proliferation.
USP and India's National Institutes for Pharmaceutical Education and Research work together to emphasize good-quality medicines and professional development.
Over-the-counter (OTC) medicines, drugs available to consumers/patients without a prescription, play an important role in our modern healthcare system. An upcoming Consumer Healthcare Products Association workshop highlights how USP collaborates with key stakeholders to help address specific needs in OTC manufacturing and testing related to drug quality. Learn more.
Learn about USP's involvement in the APEC Life Sciences Innovation Forum and how this group is improving access to quality medical products by helping Asian-Pacific economies prevent, detect and respond to spurious, substandard, falsified, falsely-labelled and counterfeit products in their supply chains.
Show 11 More